KBL Merger Corp. IV SPAC Signs Definitive Business Combination Agreement to Acquire CannBioRx Life Sciences Corp

Programs Focused on Developing Novel Anti-Inflammatory Drugs, including Scientifically Developed, Non-Psychoactive Cannabinoids that Target Key Pathways in Inflammatory Diseases.

(26/07/2019) DOWNLOAD PDF